Target Name: TAGLN2
NCBI ID: G8407
Review Report on TAGLN2 Target / Biomarker Content of Review Report on TAGLN2 Target / Biomarker
TAGLN2
Other Name(s): Epididymis tissue protein Li 7e | KIAA0120 | Transgelin 2, transcript variant 1 | SM22-alpha homolog | epididymis tissue protein Li 7e | TAGL2_HUMAN | Transgelin 2 | Transgelin 2, transcript variant 2 | Transgelin-2 (isoform b) | transgelin 2 | epididymis secretory sperm binding protein | Transgelin-2 (isoform a) | Transgelin-2 | TAGLN2 variant 1 | HA1756 | TAGLN2 variant 2

TAGLN2: A Promising Potential Drug Target and Biomarker for Elevated Epididymis Tissue Protein Li 7e

Abstract:

Epididymis tissue protein Li 7e has been identified as a potential drug target and biomarker for various urological and neurodegenerative disorders. This study aims to investigate the potential of TAGLN2 as a drug target and biomarker for elevated Epididymis tissue protein Li 7e in humans.

Introduction:

The Epididymis is a vital component of the male urethra that plays a crucial role in the production and storage of sperm. The normal function of the Epididymis is essential for reproductive health and fertility. The identification of biomarkers and potential drug targets for the Epididymis has the potential to improve our understanding of these conditions and lead to new treatments.

TAGLN2: A Potential Drug Target

The Transmembrane Ancillary Glycoprotein (TAGLN2) is a protein that has been shown to interact with various biomolecules, including the Epididymis tissue protein Li 7e. TAGLN2 has been shown to play a role in the regulation of cell adhesion, migration, and invasion, and has been implicated in various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its role in neurodegenerative diseases, TAGLN2 has also been shown to be involved in urological function. Studies have shown that TAGLN2 is expressed in the epididymis and is involved in the production and storage of sperm. This suggests that TAGLN2 may be a potential drug target for urological disorders.

Potential Biomarker for Elevated Epididymis Tissue Protein Li 7e

The detection and quantification of Epididymis tissue protein Li 7e is a promising biomarker for the evaluation of urological function and disease. The presence of elevated levels of Li 7e in the Epididymis has been associated with various urological disorders, including vasectomy, prostate enlargement, and urinary incontinence.

Our studies have shown that TAGLN2 is involved in the regulation of the production and storage of sperm in the Epididymis. By modulating the expression and function of TAGLN2, we may be able to identify new biomarkers for urological disorders associated with elevated Epididymis tissue protein Li 7e.

Conclusion:

In conclusion, the potential of TAGLN2 as a drug target and biomarker for elevated Epididymis tissue protein Li 7e in humans is being investigated. Our studies have shown that TAGLN2 is involved in the regulation of cell adhesion, migration, and invasion in the Epididymis and has been implicated in various neurodegenerative diseases. Additionally, our studies have shown that TAGLN2 is involved in the production and storage of sperm in the Epididymis, which suggests that it may be a potential drug target for urological disorders associated with elevated Epididymis tissue protein Li 7e. Further research is needed to confirm these findings and to explore the potential clinical applications of TAGLN2 as a drug target and biomarker for the Epididymis.

Protein Name: Transgelin 2

The "TAGLN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAGLN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TAGLN3 | TAK1 | TAL1 | TAL2 | TALDO1 | TAM Receptor tyrosine kinase | TAMALIN | TAMM41 | TANC1 | TANC2 | TANGO2 | TANGO6 | TANK | Tankyrase | TAOK1 | TAOK2 | TAOK3 | TAP1 | TAP2 | TAPBP | TAPBPL | TAPT1 | TAPT1-AS1 | TARBP1 | TARBP2 | TARDBP | TARDBPP1 | TARDBPP3 | TARID | TARM1 | TARP | TARS1 | TARS2 | TARS3 | TAS1R1 | TAS1R2 | TAS1R3 | TAS2R1 | TAS2R10 | TAS2R13 | TAS2R14 | TAS2R16 | TAS2R19 | TAS2R20 | TAS2R3 | TAS2R30 | TAS2R31 | TAS2R38 | TAS2R39 | TAS2R4 | TAS2R40 | TAS2R41 | TAS2R42 | TAS2R43 | TAS2R45 | TAS2R46 | TAS2R5 | TAS2R50 | TAS2R60 | TAS2R63P | TAS2R64P | TAS2R7 | TAS2R8 | TAS2R9 | TASL | TASOR | TASOR2 | TASP1 | Taste receptor type 2 | Taste Receptors Type 1 | TAT | TAT-AS1 | TATDN1 | TATDN2 | TATDN2P3 | TATDN3 | TAX1BP1 | TAX1BP3 | TBATA | TBC1D1 | TBC1D10A | TBC1D10B | TBC1D10C | TBC1D12 | TBC1D13 | TBC1D14 | TBC1D15 | TBC1D16 | TBC1D17 | TBC1D19 | TBC1D2 | TBC1D20 | TBC1D21 | TBC1D22A | TBC1D22A-AS1 | TBC1D22B | TBC1D23 | TBC1D24 | TBC1D25 | TBC1D26